ObsEva News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.04.23	ObsEva Announces Change of Central Securities Depositary (GlobeNewswire)
31.03.23	ObsEva Files Year End 2022 Financial Statements (GlobeNewswire)
15.03.23	ObsEva's Common Shares To Be Suspended By Nasdaq On March 23 (RTTNews)
15.03.23	ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023 (GlobeNewswire)
13.03.23	ObsEva Names Fabien De Ladonchamps CEO, Ernest Loumaye Interim Chairman (RTTNews)
13.03.23	ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland (GlobeNewswire)
24.02.23	ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland (GlobeNewswire)
19.12.22	ObsEva SA Announces Dismissal Of Moratorium Proceedings By Court In Geneva (RTTNews)
22.11.22	ObsEva Announces Sale Of Ebopiprant Royalty And Milestone License To XOMA (RTTNews)
22.11.22	ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million (GlobeNewswire)
26.10.22	ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings (GlobeNewswire)
13.10.22	ObsEva : China Approves Yuyuan Bioscience's IND Application For Phase 1 Trial Of Nolasiban (RTTNews)
13.10.22	ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China (GlobeNewswire)
13.09.22	ObsEva Announces Progress on Restructuring Initiatives (GlobeNewswire)
27.08.22	Biotech Stocks Facing FDA Decision In September (RTTNews)
22.08.22	ObsEva Receives Nasdaq Non-Compliance Notice (GlobeNewswire)
17.08.22	ObsEva Files Second Quarter 2022 Financial Statements (GlobeNewswire)
01.08.22	ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing (GlobeNewswire)
29.07.22	ObsEva Announces Management Change (GlobeNewswire)
27.07.22	ObsEva Announces Corporate Updates (GlobeNewswire)
27.07.22	ObsEva Announces Corporate Updates (GlobeNewswire)
28.06.22	ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids (GlobeNewswire)
17.06.22	ObsEva : European Commission Approves Yselty To Treat Uterine Fibroids (RTTNews)
17.06.22	ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids (GlobeNewswire)
27.05.22	ObsEva Announces Corporate Updates (GlobeNewswire)
25.05.22	ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses (GlobeNewswire)
19.05.22	ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors (GlobeNewswire)
19.05.22	ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18, 2022 (GlobeNewswire)
17.05.22	ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
16.05.22	ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference (GlobeNewswire)
12.05.22	ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update (GlobeNewswire)
09.05.22	ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting (GlobeNewswire)
02.05.22	ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer (GlobeNewswire)
25.04.22	ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids (GlobeNewswire)
07.04.22	ObsEva Annual General Meeting 2022 (GlobeNewswire)
31.03.22	ObsEva Annual Report 2021 (GlobeNewswire)
22.03.22	ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe End (GlobeNewswire)
22.03.22	ObsEva Announces Addl Efficacy Results For Linzagolix On Endometriosis-associated Pain (RTTNews)
22.03.22	ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe End (GlobeNewswire)
10.03.22	ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
10.02.22	ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix (GlobeNewswire)
04.02.22	ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids (GlobeNewswire)
01.02.22	Pre-market Movers: KSCP, OBSV, SPIR, SI, CIAN… (RTTNews)
01.02.22	ObsEva Appoints Katja Buhrer as Chief Strategy Officer (GlobeNewswire)
31.01.22	Pre-market Movers: FGI, IMPP, KSCP, WKEY, HAPP… (RTTNews)
28.01.22	ObsEva Announces Corporate Updates (GlobeNewswire)
06.01.22	Pre-market Movers: KAVL, ATHE, BLI, PSTV, CNSP… (RTTNews)
06.01.22	ObsEva: Linzagolix Phase 3 Trial Shows Positive Topline Results In Women With Moderate-to-severe EAP (RTTNews)
06.01.22	ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain (GlobeNewswire)
03.01.22	ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

27.09.24		Gewinne in Zürich: SPI präsentiert sich zum Ende des Freitagshandels fester
27.09.24		SPI aktuell: SPI klettert
24.09.24		Gewinne in Zürich: SPI beendet den Dienstagshandel mit Gewinnen
23.09.24		Gewinne in Zürich: SPI bewegt schlussendlich im Plus
23.09.24		Gute Stimmung in Zürich: SPI notiert im Plus
21.08.24		Anleger in Zürich halten sich zurück: SPI beendet die Sitzung im Minus
15.08.24		Börse Zürich in Grün: SPI legt zum Handelsende zu
15.08.24		Börse Zürich in Grün: SPI in der Gewinnzone

27.09.24

Gewinne in Zürich: SPI präsentiert sich zum Ende des Freitagshandels fester

27.09.24

SPI aktuell: SPI klettert

24.09.24

Gewinne in Zürich: SPI beendet den Dienstagshandel mit Gewinnen

23.09.24

Gewinne in Zürich: SPI bewegt schlussendlich im Plus

23.09.24

Gute Stimmung in Zürich: SPI notiert im Plus

21.08.24

Anleger in Zürich halten sich zurück: SPI beendet die Sitzung im Minus

15.08.24

Börse Zürich in Grün: SPI legt zum Handelsende zu

15.08.24

Börse Zürich in Grün: SPI in der Gewinnzone

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Sonova Hldg	310.80	2.24 %	K V
Part Grp Hldg	1’250.00	1.79 %	K V
Novartis	92.70	1.25 %	K V
Geberit	523.00	1.24 %	K V
Roche Hldg G	253.70	1.04 %	K V
CieFinRichemont	117.80	0.13 %	K V
Zurich Insur Gr	547.40	-0.04 %	K V
UBS Group	28.11	-0.11 %	K V
Swiss Life Hldg	726.40	-0.11 %	K V
Kuehne+Nagel Int	207.30	-0.34 %	K V

Nachrichten zu ObsEva AG

Aktien Top/Flop

ObsEva Peer Group Nachrichten

Meistgelesene Nachrichten